mRNA deadenylation and telomere disease

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 1796-1798

  Mason, Philip J ^a   Bessler, Monica ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; POLYADENYLIC ACID SPECIFIC RIBONUCLEASE; PROTEIN P53; RIBONUCLEASE; UNCLASSIFIED DRUG; EXORIBONUCLEASE;

CHEMICAL MODIFICATION; DEADENYLATION; DNA DAMAGE; DYSKERATOSIS CONGENITA; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; NOTE; PRIORITY JOURNAL; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; DEFICIENCY; FEMALE; GENETICS; MALE; MUTATION;

DYSKERATOSIS CONGENITA; EXORIBONUCLEASES; FEMALE; HUMANS; MALE; MUTATION; TELOMERE HOMEOSTASIS;

EID: 84929018125     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81506     Document Type: Note

References (24)

1. Zinsser F. Atrophia Cutis Reticularis cum Pigmentations, Dystrophia Unguium et Leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi.) Ikonographia Dermatologica. 1910;5:219-223.
2. Connor JM, Gatherer D, Gray FC, Pirrit LA, Affara NA. Assignment of the gene for dyskeratosis congenita to Xq28. Hum Genet. 1986;72(4):348-351.
3. Knight SW, et al. 1.4 Mb candidate gene region for X linked dyskeratosis congenita defined by combined haplotype and X chromosome inactivation analysis. J Med Genet. 1998;35(12):993-996.
4. Heiss NS, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19(1):32-38.
5. Lafontaine DL, Bousquet-Antonelli C, Henry Y, Caizergues-Ferrer M, Tollervey D. The box H + ACA snoRNAs carry Cbf5p, the putative rRNA pseudouridine synthase. Genes Dev. 1998;12(4):527-537.
6. Watkins NJ, et al. Cbf5p, a potential pseudouridine synthase, and Nhp2p, a putative RNA-binding protein, are present together with Gar1p in all H BOX/ACA-motif snoRNPs and constitute a common bipartite structure. RNA. 1998;4(12):1549-1568.
7. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402(6761):551-555.
8. Vulliamy T, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001;413(6854):432-435.
9. Armanios M, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A. 2005;102(44):15960-15964.
10. Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A, Dokal I. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis. 2005;34(3):257-263.
11. Gramatges MM, Bertuch AA. Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Transl Res. 2013;162(6):353-363.
12. Guo Y, et al. Inherited bone marrow failure associated with germline mutation of ACD, the gene encoding telomere protein TPP1. Blood. 2014;124(18):2767-2774.
13. Alter BP, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010;150(2):179-188.
14. Tummala H, et al. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. J Clin Invest. 2015;125(5):2151-2160.
15. Buiting K, Korner C, Ulrich B, Wahle E, Horsthemke B. The human gene for the poly(A)-specific ribonuclease (PARN) maps to 16p13 and has a truncated copy in the Prader-Willi/Angelman syndrome region on 15q11→q13. Cytogenet Cell Genet. 1999;87(1-2):125-131.
16. Cevher MA, et al. Nuclear deadenylation/polyadenylation factors regulate 3′ processing in response to DNA damage. EMBO J. 2010;29(10):1674-1687.
17. Lee JE, Lee JY, Trembly J, Wilusz J, Tian B, Wilusz CJ. The PARN deadenylase targets a discrete set of mRNAs for decay and regulates cell motility in mouse myoblasts. PLoS Genet. 2012;8(8):e1002901.
18. Devany E, Zhang X, Park JY, Tian B, Kleiman FE. Positive and negative feedback loops in the p53 and mRNA 3′ processing pathways. Proc Natl Acad Sci U S A. 2013;110(9):3351-3356.
19. Ceccaldi R, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11(1):36-49.
20. Dumitriu B, Young NS. Damage control and its costs: BM failure in Fanconi anemia stems from overactive p53/p21. Cell Stem Cell. 2012;11(1):7-8.
21. Boultwood J, Pellagatti A, Wainscoat JS. Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome. Adv Biol Regul. 2012;52(1):196-203.
22. Ogden GR, Lane DP, Chisholm DM. p53 expression in dyskeratosis congenita: a marker for oral premalignancy? J Clin Pathol. 1993;46(2):169-170.
23. Westin ER, Aykin-Burns N, Buckingham EM, Spitz DR, Goldman FD, Klingelhutz AJ. The p53/p21(WAF/CIP) pathway mediates oxidative stress and senescence in dyskeratosis congenita cells with telomerase insufficiency. Antioxid Redox Signal. 2011;14(6):985-997.
24. Simeonova I, et al. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Rep. 2013;3(6):2046-2058.